Tema Oncology ETF (NASDAQ:CANC – Get Free Report) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 7,400 shares, a growth of 13.8% from the December 31st total of 6,500 shares. Based on an average trading volume of 11,800 shares, the days-to-cover ratio is currently 0.6 days.
Tema Oncology ETF Stock Down 0.8 %
Shares of Tema Oncology ETF stock opened at $25.69 on Monday. The stock’s fifty day moving average is $25.56 and its two-hundred day moving average is $27.44. The company has a market capitalization of $65.51 million, a PE ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a 52 week low of $23.97 and a 52 week high of $30.11.
Tema Oncology ETF Dividend Announcement
The firm also recently disclosed a dividend, which was paid on Thursday, December 12th. Shareholders of record on Wednesday, December 11th were given a $0.7283 dividend. The ex-dividend date was Wednesday, December 11th.
Hedge Funds Weigh In On Tema Oncology ETF
Tema Oncology ETF Company Profile
The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.
See Also
- Five stocks we like better than Tema Oncology ETF
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- 3X-Leveraged ETFs: Amplify Returns With These 3 Top Picks
- How to Calculate Inflation Rate
- 3 Underrated Robotics Stocks Poised for Major Growth
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Reshoring Riches: Investing in Made in America 2.0
Receive News & Ratings for Tema Oncology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tema Oncology ETF and related companies with MarketBeat.com's FREE daily email newsletter.